thiazoles has been researched along with Granulocytic Leukemia, Chronic, Stable Phase in 72 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 18 (25.00) | 29.6817 |
| 2010's | 53 (73.61) | 24.3611 |
| 2020's | 1 (1.39) | 2.80 |
| Authors | Studies |
|---|---|
| De Lavallade, H; Dillon, R; Green, A; Harrington, P; Harrison, C; Hussain, F; Kordasti, S; McLornan, DP; Ong, M; Radia, D; Raj, K; Rousselot, P; Verde, A | 1 |
| Koutna, I; Mayer, J; Potesil, D; Potesilova, M; Simara, P; Stejskal, S; Tesarova, L; Zdrahal, Z | 1 |
| Hu, JD; Huang, XJ; Shen, ZX; Wang, JX; Zhou, L | 1 |
| Erben, P; Hochhaus, A; Klag, T; La Rosée, P; Leitner, A; Martiat, P; Müller, MC; Saussele, S; Schenk, T | 1 |
| Costa, FF; De Souza, CA; Fachel, AA; Moreira, YB; Pagnano, KB; Silveira, RA; Verjovski-Almeida, S | 1 |
| Borthakur, G; Burger, JA; Cortes, JE; Falchi, L; Garcia-Manero, G; Jabbour, EJ; Kantarjian, HM; Luthra, R; O'Brien, S; Quintás-Cardama, A; Ravandi-Kashani, F; Verma, D; Verstovsek, S; Wang, X | 1 |
| Saglio, G; Savona, MR | 1 |
| Clark, R; Drummond, M; Gallipoli, P; Heaney, N; Holyoake, TL; Hughes, T; McLintock, L; Michor, F; Nicolini, FE; Paul, J; Stobo, J; Tighe, J; Wilson, G | 1 |
| Jabbour, E; Lipton, JH | 1 |
| Bradley-Garelik, MB; Chuah, CT; Kim, DW; Nakamae, H; Shen, ZX | 1 |
| Fujisawa, S; Inokuchi, K; Iwase, O; Kozai, Y; Kumagai, T; Matsuki, E; Nishiwaki, K; Oba, K; Ohashi, K; Okamoto, S; Sakamaki, H; Sakamoto, J; Shinagawa, A; Shirasugi, Y; Takeuchi, J; Wakita, H; Yano, S; Yoshida, C | 1 |
| Akiyama, H; Fujisawa, S; Ishida, Y; Ishizawa, K; Matsue, K; Nakamae, H; Ogura, M; Onishi, S; Takamatsu, Y; Tanimoto, M; Taniwaki, M; Usuki, K; Utsunomiya, A | 1 |
| Bengió, RM; Bianchini, M; Ferri, CA; Gonzalez, MS; Larripa, IB; Moiraghi, EB; Noriega, MF | 1 |
| Betts, KA; Chen, L; DeAngelo, DJ; Galebach, P; Reichmann, WM; Signorovitch, JE; Thomason, D; Wu, EQ | 1 |
| Alimena, G; Breccia, M; Colafigli, G; Diverio, D; Latagliata, R; Mancini, M; Molica, M; Tafuri, A | 1 |
| Alvarez-Larrán, A; Bautista, G; Bobillo, S; Boqué, C; Cuevas, B; de Las Heras, N; Deben, G; Fernandez, A; García Garay, Mdel C; García-Gutiérrez, V; Giraldo, P; Guinea, JM; Iglesias Pérez, A; Lopez Lorenzo, JL; Maestro, B; Martin Mateos, ML; Martinez-Trillos, A; Mata, I; Ortega, F; Portero, A; Ramirez Sánchez, MJ; Romero, E; Romo Collado, A; Ruiz, C; Sebrango, A; Steegmann, JL; Tallón, J; Valencia, S | 1 |
| Dahl, J; Jabbour, EJ; Mace, ML | 1 |
| Chiba, S; Fujisawa, S; Igarashi, T; Inokuchi, K; Iriyama, N; Kawakami, K; Kouzai, Y; Kumagai, T; Morita, S; Ohyashiki, K; Okamoto, S; Sakamaki, H; Sakamoto, J; Taguchi, J; Takezako, N; Wakita, H; Yano, S; Yoshida, C | 1 |
| Bleickardt, E; Charbonnier, A; Collins, RH; Deininger, M; Dorlhiac-Llacer, PE; Francis, S; Hochhaus, A; Hughes, T; Kantarjian, HM; Khoroshko, N; Khoury, HJ; Kim, DW; Milone, JH; Otero, I; Paquette, RL; Réa, D; Shah, NP; Silver, RT; Strauss, L; Vela-Ojeda, J | 1 |
| Feola, M; Gallamini, A; Mattei, D; Mordini, N; Orzan, F; Rapezzi, D | 1 |
| Cayuela, JM; Dombret, H; Maarek, O; Raffoux, E; Rea, D | 1 |
| Ando, K; Fujisawa, S; Iida, S; Ishizawa, KI; Jinnai, I; Miyawaki, S; Miyazaki, Y; Morishima, Y; Motoji, T; Nagai, T; Naoe, T; Ohnishi, K; Ohno, R; Okada, M; Okamoto, S; Sakamaki, H; Seriu, T; Tanimoto, M; Taniwaki, M; Tobinai, K; Uoshima, N; Usui, N; Utsunomiya, A | 1 |
| Snyder, DS | 1 |
| Cortes, J; Kantarjian, H; Kornblau, S; O'Brien, S; Quintás-Cardama, A; Ravandi, F; Thomas, D; Vidal-Senmache, G; Wierda, W | 1 |
| Ahmed, N; Cang, S; Liu, D; Mathews, T; Primanneni, S; Seiter, K; Tan, J | 1 |
| Jillella, AP; Salama, ME; Ustun, C | 1 |
| Mauro, MJ | 1 |
| Bleickardt, E; Cortes, J; Dejardin, D; Hamerschlak, N; Holowiecki, J; Hughes, T; Jootar, S; Kantarjian, H; Lévy, V; Pasquini, R; Shah, NP | 1 |
| Bleickardt, E; Branford, S; Hanfstein, B; Hochhaus, A; Hughes, TP; Kantarjian, HM; Kim, DW; Lambert, A; Lipton, JH; Müller, MC; Radich, J; Rousselot, P | 1 |
| Cortes, JE; Khoury, HJ; Matloub, Y; Paquette, RL; Porkka, K; Sinha, R | 1 |
| Borthakur, G; Cortes, JE; Jabbour, E; Jones, D; Kantarjian, H; Koller, C; O'Brien, S; Ravandi, F; Shan, J; Walker, B; Zhao, W | 1 |
| Cortes, J; Hochhaus, A; Kantarjian, HM; La Rosée, P | 1 |
| Enrico, A; Hochhaus, A; Kantarjian, H; Khoury, HJ; Kim, DW; Lambert, A; Llacer, PE; Matloub, Y; Müller, MC; Rousselot, P; Shah, NP; Silver, RT; Vela-Ojeda, J | 1 |
| Alvarado, Y; Cortes, J; Giles, FJ; Swords, R | 1 |
| Abruzzese, E; Baccarani, M; Bhatia, R; Bosly, A; Cortes, J; Dünzinger, U; Facon, T; Fischer, T; Gallagher, NJ; Giles, FJ; Goldberg, S; Jagasia, M; Kam, GL; Kantarjian, HM; Kim, DW; Larson, RA; Mahon, FX; Marin, D; Mendrek, W; Mueller, MC; Rosti, G; Shou, Y | 1 |
| Sawyers, CL | 1 |
| Ayala, M; Baccarani, M; Bleickardt, E; Boqué, C; Bradley-Garelik, MB; Chuah, C; Cortes, J; Hochhaus, A; Huguet, F; Kantarjian, H; Mayer, J; Moiraghi, B; Nakamae, H; Pasquini, R; Shah, NP; Shah, S; Shapiro, D; Shen, Z; Szatrowski, T; Zhu, C | 1 |
| Apperley, JF; Clark, RE; Daghistani, M; De Melo, VA; Foroni, L; Gerrard, G; Goldman, JM; Khorashad, JS; Marin, D; May, PC; Milojkovic, D; Paliompeis, C; Reid, AG; Wang, L | 1 |
| Hori, A; Tanimoto, T; Tsubokura, M | 1 |
| Porkka, K; Richter, J; Simonsson, B | 1 |
| Akard, LP | 1 |
| Beyazit, Y; Haznedaroglu, IC; Kekilli, M | 1 |
| Borthakur, G; Cortes, J; Garcia-Manero, G; Jabbour, E; Kantarjian, H; O'Brien, S; Ravandi, F; Rios, MB; Shan, J; Wierda, W | 1 |
| Hughes, TP; White, DL | 1 |
| Alimena, G; Breccia, M | 1 |
| Ichikawa, K; Komatsu, N; Sato, E; Sunami, Y; Yasuda, H | 1 |
| Demarquet, M; Labussière-Wallet, H; Nicolas-Virelizier, E; Nicolini, FE | 1 |
| Alimena, G; Breccia, M; Cannella, L; Colafigli, G; De Cuia, MR; Loglisci, G; Nanni, M; Salaroli, A; Serrao, A | 1 |
| Guilhot, F; Roy, L; Tomowiak, C | 1 |
| Bagadi, S; Das, B; Pany, A; Saikia, T | 1 |
| Reed, SD | 1 |
| Hoyle, M; Liu, Z; Moxham, T; Rogers, G; Stein, K | 1 |
| Agarwal, MB; Baccarani, M; Bradley-Garelik, MB; Cortes, JE; Hochhaus, A; Ipiña, JJ; Junghanss, C; Kantarjian, HM; Kim, DW; Milone, JH; Nicolini, FE; Ogura, M; Pavlovsky, C; Robak, T; Shah, NP; Undurraga, MS; Van Droogenbroeck, J; Vellenga, E; Wang, J; Zhu, C | 1 |
| Apperley, JF; Bua, M; Foroni, L; Gerrard, G; Goldman, J; Ibrahim, AR; Marin, D; Milojkovic, D; Reid, A; Rezvani, K; Szydlo, R | 1 |
| Abbott, BL | 1 |
| Baccarani, M; Besson, N; Brümmendorf, TH; Cortes, JE; Countouriotis, A; Gambacorti-Passerini, C; Kantarjian, HM; Kelly, V; Khoury, HJ; Kim, DW; Leip, E; Zaritskey, A | 1 |
| Bolton, E; Cerny-Reiterer, S; Cramer, K; Dorrance, A; Eaves, CJ; Flis, S; Glodkowska-Mrowka, E; Hochhaus, A; Holyoake, TL; Hoser, G; Hughes, TP; Kopinski, PK; Koptyra, M; Ngaba, D; Nieborowska-Skorska, M; Penserga, T; Ray, R; Reddy, MM; Richardson, C; Sattler, M; Skorski, T; Stoklosa, T; Valent, P; van der Kuip, H; Wiktor-Jedrzejczak, W; Williams, DA | 1 |
| Cortes, J; Garcia-Manero, G; Jabbour, E; Kantarjian, H; Nazha, A; O'Brien, S; Pierce, S; Quintas-Cardama, A | 1 |
| Jootar, S | 1 |
| Hoyle, M; Liu, Z; Moxham, T; Pitt, M; Rogers, G; Stein, K; Thompson Coon, J | 1 |
| Apperley, J; Clark, RE; Foroni, L; Goldman, JM; Hedgley, C; Marin, D; Milojkovic, D; O'Brien, S; Pocock, C | 1 |
| Appelbaum, FR; Deininger, M; Druker, BJ; Emanuel, P; Kamel-Reid, S; Kopecky, KJ; Larson, RA; Lipton, J; Malnassy, G; Paietta, E; Radich, JP; Stock, W; Tallman, M; Turner, AR; Wadleigh, M | 1 |
| Abruzzese, E; Albano, F; Alimena, G; Annunziata, M; Breccia, M; Cambrin, GR; Castagnetti, F; Fanin, R; Fava, C; Gozzini, A; Latagliata, R; Luciano, L; Montefusco, E; Musto, P; Pane, F; Pregno, P; Rosti, G; Stagno, F; Tiribelli, M; Vigneri, P | 1 |
| Cortes, J | 1 |
| Kamel-Reid, S; Kim, DD; Lee, H; Lipton, JH | 1 |
| Bua, M; Clark, R; Gerrard, G; Goldman, J; Lucas, C; Marin, D; May, P; Milojkovic, D; Neelakantan, P; O'Brien, S; Paliompeis, C; Reid, A; Rezvani, K; Wang, L | 1 |
| Assouline, S; Gambacorti-Passerini, C; Laneuville, P | 1 |
| Countouriotis, A; Golenkov, A; Hamerschlak, N; Hellmann, A; Holowiecki, J; Hughes, T; Jootar, S; Kantarjian, H; Khoroshko, N; Masszi, T; Pasquini, R; Radich, J; Robak, T; Rousselot, P; Shah, N; Skotnicki, A; Zaritsky, A | 1 |
| Fausel, C | 1 |
| Booth, B; Brave, M; Bullock, J; Farrell, A; Gobburu, J; Goodman, V; Harapanhalli, R; Jiang, X; Justice, R; Kaminskas, E; Kenna, L; Men, A; Morse, D; Noory, C; Pazdur, R; Pope, S; Ramchandani, R; Saber, H; Sridhara, R; Timmer, W | 1 |
| Apperley, JF; Baccarani, M; Cervantes, F; Corm, S; Countouriotis, AM; Deininger, M; Dombret, H; Ezzeddine, R; Goldberg, SL; Hochhaus, A; Hughes, T; Kantarjian, HM; Larson, RA; Lipton, JH; Müller, MC; Niederwieser, D; Roy, L; Shah, NP; Silver, RT; Stone, RM | 1 |
| Barlow, A; Doig, A; Drummond, MW; Robertson, M; Stewart, W | 1 |
14 review(s) available for thiazoles and Granulocytic Leukemia, Chronic, Stable Phase
| Article | Year |
|---|---|
Identifying the time to change BCR-ABL inhibitor therapy in patients with chronic myeloid leukemia.
Topics: Benzamides; Clinical Trials as Topic; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Piperazines; Pyrimidines; Retrospective Studies; Thiazoles; Treatment Outcome | 2013 |
A critical review of trials of first-line BCR-ABL inhibitor treatment in patients with newly diagnosed chronic myeloid leukemia in chronic phase.
Topics: Antineoplastic Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dasatinib; Fusion Proteins, bcr-abl; Humans; Leukemia, Myeloid, Chronic-Phase; Protein Kinase Inhibitors; Pyrimidines; Research Design; Thiazoles; Treatment Outcome | 2013 |
Which tyrosine-kinase inhibitor to use first in chronic phase chronic myelogenous leukemia?
Topics: Antineoplastic Agents; Benzamides; Clinical Trials, Phase III as Topic; Dasatinib; Drug Resistance, Neoplasm; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2015 |
New approved dasatinib regimen available for clinical use.
Topics: Clinical Trials, Phase III as Topic; Dasatinib; Drug Resistance, Neoplasm; Humans; Leukemia, Myeloid, Chronic-Phase; Pleural Effusion; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Thrombocytopenia | 2009 |
t(3;9;22) 3-way chromosome translocation in chronic myeloid leukemia is associated with poor prognosis.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 3; Chromosomes, Human, Pair 9; Cyclophosphamide; Dasatinib; Dexamethasone; Disease Progression; Doxorubicin; Drug Resistance, Neoplasm; Fatal Outcome; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myeloid, Chronic-Phase; Male; Methotrexate; Middle Aged; Philadelphia Chromosome; Piperazines; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Rituximab; Thiazoles; Translocation, Genetic; Vincristine | 2009 |
Response dynamics in chronic-phase chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Cytogenetic Analysis; Dasatinib; Disease Progression; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Outcome | 2009 |
Optimizing therapy for patients with chronic myelogenous leukemia in chronic phase.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2010 |
Second-generation tyrosine kinase inhibitors as therapy for chronic myeloid leukemia.
Topics: Animals; Benzamides; Clinical Trials as Topic; Dasatinib; Drug Delivery Systems; Drug Design; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drugs, Investigational; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Mice; Multicenter Studies as Topic; Mutation; Piperazines; Protein Isoforms; Protein Kinase Inhibitors; Pyrimidines; Signal Transduction; Thiazoles | 2007 |
Predicting the response of CML patients to tyrosine kinase inhibitor therapy.
Topics: ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzamides; Dasatinib; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Organic Cation Transporter 1; Piperazines; Polymorphism, Single Nucleotide; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2011 |
Activity and safety of dasatinib as second-line treatment or in newly diagnosed chronic phase chronic myeloid leukemia patients.
Topics: Clinical Trials, Phase III as Topic; Dasatinib; Fusion Proteins, bcr-abl; Humans; Leukemia, Myeloid, Chronic-Phase; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2011 |
[A therapeutic improvement: second generation tyrosine kinase inhibitors (TKI 2) in the treatment of chronic myelogenous leukemia].
Topics: Aniline Compounds; Antineoplastic Agents; Blast Crisis; Dasatinib; Humans; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myeloid, Chronic-Phase; Nitriles; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Thiazoles | 2011 |
Dasatinib: from treatment of imatinib-resistant or -intolerant patients with chronic myeloid leukemia to treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia.
Topics: Benzamides; Clinical Trials, Phase III as Topic; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2012 |
Dasatinib and nilotinib for imatinib-resistant or -intolerant chronic myeloid leukaemia: a systematic review and economic evaluation.
Topics: Benzamides; Blast Crisis; Clinical Trials as Topic; Cost-Benefit Analysis; Dasatinib; Decision Support Techniques; Disease Progression; Drug Resistance, Neoplasm; Health Care Costs; Humans; Imatinib Mesylate; Incidence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myeloid, Chronic-Phase; Models, Economic; Piperazines; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Quality of Life; Thiazoles | 2012 |
Targeted chronic myeloid leukemia therapy: Seeking a cure.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Dasatinib; Drug Resistance, Neoplasm; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2007 |
21 trial(s) available for thiazoles and Granulocytic Leukemia, Chronic, Stable Phase
| Article | Year |
|---|---|
[Preliminary comparison of efficacy and safety of dasatinib and imatinib in newly diagnosed chronic myeloid leukemia].
Topics: Adult; Aged; Benzamides; Dasatinib; Female; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Piperazines; Pyrimidines; Survival Rate; Thiazoles; Treatment Outcome; Young Adult | 2013 |
Safety and efficacy of pulsed imatinib with or without G-CSF versus continuous imatinib in chronic phase chronic myeloid leukaemia patients at 5 years follow-up.
Topics: Benzamides; Cell Cycle; Dasatinib; Drug Substitution; Drug Synergism; Follow-Up Studies; Fusion Proteins, bcr-abl; Granulocyte Colony-Stimulating Factor; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Piperazines; Protein Kinase Inhibitors; Pulse Therapy, Drug; Pyrimidines; Thiazoles; Treatment Outcome | 2013 |
Efficacy and safety of dasatinib versus imatinib in the East Asian subpopulation of the DASISION trial of newly diagnosed chronic myeloid leukemia in chronic phase.
Topics: Antineoplastic Agents; Asian People; Benzamides; Dasatinib; DNA Mutational Analysis; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Outcome | 2014 |
Efficacy and safety of dasatinib versus imatinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP): Subset analysis of the DASISION trial with 2-year follow-up.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Japan; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Survival Analysis; Thiazoles; Young Adult | 2014 |
One-year and long-term molecular response to nilotinib and dasatinib for newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison.
Topics: Aged; Antineoplastic Agents; Dasatinib; Disease Progression; Female; Humans; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Molecular Targeted Therapy; Propensity Score; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Treatment Outcome | 2015 |
Early cytotoxic lymphocyte expansion contributes to a deep molecular response to dasatinib in patients with newly diagnosed chronic myeloid leukemia in the chronic phase: results of the D-first study.
Topics: Antigens, CD; Antineoplastic Agents; Dasatinib; Fusion Proteins, bcr-abl; Gene Expression; Humans; Immunophenotyping; Killer Cells, Natural; Leukemia, Myeloid, Chronic-Phase; Lymphocyte Count; Lymphocytosis; Prospective Studies; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; ROC Curve; T-Lymphocytes, Cytotoxic; T-Lymphocytes, Regulatory; Thiazoles | 2015 |
Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzamides; Dasatinib; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Survival Rate; Thiazoles; Treatment Outcome | 2008 |
Phase 1/2 clinical study of dasatinib in Japanese patients with chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia.
Topics: Adult; Aged; Antineoplastic Agents; Asian People; Dasatinib; Fusion Proteins, bcr-abl; Humans; Leukemia, Myeloid, Chronic-Phase; Middle Aged; Mutation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Thiazoles | 2009 |
Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Hemorrhagic Disorders; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Piperazines; Platelet Count; Pyrimidines; Risk Factors; Thiazoles; Withholding Treatment; Young Adult | 2009 |
Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R).
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Cross-Over Studies; Dasatinib; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Withholding Treatment | 2009 |
Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Dasatinib; Humans; Leukemia, Myeloid, Chronic-Phase; Middle Aged; Pyrimidines; Thiazoles; Young Adult | 2010 |
Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or int
Topics: Benzamides; Cytogenetic Analysis; Dasatinib; Drug Administration Schedule; Drug Resistance; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2010 |
Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy.
Topics: Adult; Aged; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; International Agencies; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Salvage Therapy; Survival Rate; Thiazoles; Treatment Outcome; Young Adult | 2010 |
Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Blast Crisis; Dasatinib; Disease Progression; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Young Adult | 2010 |
Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Cytogenetic Analysis; Dasatinib; Disease-Free Survival; Female; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Piperazines; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Treatment Failure; Treatment Outcome; Young Adult | 2011 |
Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION).
Topics: Age of Onset; Algorithms; Antineoplastic Agents; Benzamides; Cytogenetic Analysis; Dasatinib; DNA Mutational Analysis; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Middle Aged; Neoadjuvant Therapy; Piperazines; Pyrimidines; Thiazoles; Time Factors; Treatment Outcome | 2012 |
Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure.
Topics: Adult; Aged; Algorithms; Aniline Compounds; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chemotherapy, Adjuvant; Dasatinib; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Nitriles; Piperazines; Pyrimidines; Quinolines; Thiazoles; Treatment Failure; Young Adult | 2012 |
Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Dasatinib; Female; Genes, abl; Humans; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Predictive Value of Tests; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; Thiazoles; Time Factors; Transcription, Genetic; Young Adult | 2012 |
A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Dasatinib; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Recurrence; Thiazoles; Treatment Outcome; Young Adult | 2012 |
Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies.
Topics: Acebutolol; Antineoplastic Agents; Benzamides; Dasatinib; Fusion Proteins, bcr-abl; Genetic Testing; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Piperazines; Predictive Value of Tests; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Pyrimidines; Risk Factors; Thiazoles; Time Factors; Treatment Outcome | 2013 |
Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Cytogenetic Analysis; Dasatinib; Disease-Free Survival; Drug Resistance; Edema; Female; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Pancytopenia; Piperazines; Pleural Effusion; Pyrimidines; Salvage Therapy; Thiazoles; Treatment Outcome | 2007 |
37 other study(ies) available for thiazoles and Granulocytic Leukemia, Chronic, Stable Phase
| Article | Year |
|---|---|
Differential inhibition of T-cell receptor and STAT5 signaling pathways determines the immunomodulatory effects of dasatinib in chronic phase chronic myeloid leukemia.
Topics: Dasatinib; Humans; Interleukin-2; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Protein Kinase Inhibitors; Pyrimidines; Receptors, Antigen, T-Cell; Signal Transduction; src-Family Kinases; STAT5 Transcription Factor; Thiazoles | 2023 |
Apoptosis in chronic myeloid leukemia cells transiently treated with imatinib or dasatinib is caused by residual BCR-ABL kinase inhibition.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Apoptosis; Benzamides; Biological Transport; Bone Marrow Cells; Cell Line, Tumor; Dasatinib; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Kinetics; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Neoplastic Stem Cells; Nuclear Proteins; Osmolar Concentration; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Pyrimidines; Thiazoles; Tumor Cells, Cultured | 2013 |
Improved tolerability by a modified intermittent treatment schedule of dasatinib for patients with chronic myeloid leukemia resistant or intolerant to imatinib.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Dasatinib; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Piperazines; Pyrimidines; Retrospective Studies; Thiazoles | 2013 |
Protein-coding genes and long noncoding RNAs are differentially expressed in dasatinib-treated chronic myeloid leukemia patients with resistance to imatinib.
Topics: Adult; Aged; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Piperazines; Pyrimidines; RNA, Long Noncoding; Thiazoles | 2014 |
Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Dasatinib; Disease-Free Survival; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Neoplasm Proteins; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Real-Time Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Survival Analysis; Thiazoles; Treatment Outcome; Young Adult | 2013 |
Relative increase in lymphocytes from as early as 1 month predicts improved response to dasatinib in chronic-phase chronic myelogenous leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Dasatinib; Female; Fusion Proteins, bcr-abl; Humans; Immunophenotyping; Leukemia, Myeloid, Chronic-Phase; Lymphocyte Count; Lymphocyte Subsets; Male; Middle Aged; Neoplasm Staging; Phenotype; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Time Factors; Treatment Outcome; Young Adult | 2014 |
Clinical activity of ponatinib in one patient with chronic myeloid leukemia in chronic phase with e19a2 transcript and T315I mutation.
Topics: Antineoplastic Agents; Dasatinib; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Gene Expression; Humans; Hydroxyurea; Imidazoles; Leukemia, Myeloid, Chronic-Phase; Middle Aged; Mutation; Pyridazines; Pyrimidines; RNA, Messenger; Thiazoles; Treatment Outcome | 2015 |
Chronic phase chronic myeloid leukemia patients who failed interferon alpha and switched to imatinib: Long-term 9-year follow-up of 134 patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Drug Substitution; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Piperazines; Pyrimidines; Survival Analysis; Thiazoles | 2015 |
Bosutinib shows low cross intolerance, in chronic myeloid leukemia patients treated in fourth line. Results of the Spanish compassionate use program.
Topics: Adult; Aged; Aniline Compounds; Antineoplastic Agents; Benzamides; Compassionate Use Trials; Dasatinib; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Nitriles; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Retrospective Studies; Spain; Survival Analysis; Thiazoles | 2015 |
Reversible dasatinib-induced pulmonary arterial hypertension and right ventricle failure in a previously allografted CML patient.
Topics: Dasatinib; Heart Failure; Hematopoietic Stem Cell Transplantation; Humans; Hypertension, Pulmonary; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Pyrimidines; Thiazoles; Transplantation, Homologous; Ventricular Dysfunction, Right | 2009 |
Sustained major molecular response in the absence of any antileukaemic therapy after dasatinib treatment and autologous peripheral blood stem cell transplantation in a patient with imatinib-resistant myeloblastic-phase chronic myeloid leukaemia.
Topics: Benzamides; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Middle Aged; Peripheral Blood Stem Cell Transplantation; Piperazines; Pyrimidines; Remission Induction; Thiazoles; Transplantation, Autologous | 2009 |
Dasatinib induces complete cytogenetic response and loss of F359C in an imatinib resistant chronic myelocytic leukemia patient.
Topics: Adult; Base Sequence; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Male; Molecular Sequence Data; Mutation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2009 |
Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzamides; Dasatinib; DNA Mismatch Repair; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Failure | 2009 |
Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion.
Topics: Adult; Aged; Antineoplastic Agents; Dasatinib; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Chronic-Phase; Middle Aged; Pleural Effusion; Protein Kinase Inhibitors; Pyrimidines; Risk Factors; Thiazoles | 2010 |
Even better kinase inhibitors for chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2010 |
EVI-1 oncogene expression predicts survival in chronic-phase CML patients resistant to imatinib treated with second-generation tyrosine kinase inhibitors.
Topics: Benzamides; Blast Crisis; Dasatinib; DNA-Binding Proteins; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myeloid, Chronic-Phase; Male; MDS1 and EVI1 Complex Locus Protein; Middle Aged; Piperazines; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogenes; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Salvage Therapy; Survival Rate; Thiazoles; Transcription Factors | 2010 |
Second-generation BCR-ABL kinase inhibitors in CML.
Topics: Benzamides; Dasatinib; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Piperazines; Pyrimidines; Remission Induction; Thiazoles; Time Factors | 2010 |
Second-generation BCR-ABL kinase inhibitors in CML.
Topics: Benzamides; Dasatinib; Disease Progression; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Intention to Treat Analysis; Leukemia, Myeloid, Chronic-Phase; Piperazines; Pyrimidines; Thiazoles | 2010 |
Second-generation BCR-ABL kinase inhibitors in CML.
Topics: Benzamides; Dasatinib; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Piperazines; Pyrimidines; Survival Rate; Thiazoles | 2010 |
Second-generation BCR-ABL kinase inhibitors in CML.
Topics: Benzamides; Dasatinib; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Piperazines; Pyrimidines; Remission Induction; Thiazoles | 2010 |
[Hemorrhagic colitis caused by dasatinib following cytomegalovirus enterocolitis in a patient with chronic myelogenous leukemia in the second chronic phase].
Topics: Adult; Colitis; Cytomegalovirus Infections; Dasatinib; Enterocolitis; Female; Gastrointestinal Hemorrhage; Humans; Leukemia, Myeloid, Chronic-Phase; Pyrimidines; Thiazoles | 2011 |
Trisomy 8 in Philadelphia chromosome negative cell preceding the evolution of a Philadelphia chromosome positive clone with the same additional change during imatinib treatment: revisiting the role of genetic instability in chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Chromatography, High Pressure Liquid; Chromosomes, Human, Pair 8; Clone Cells; Dasatinib; DNA Mutational Analysis; Genomic Instability; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Molecular Targeted Therapy; Philadelphia Chromosome; Piperazines; Preleukemia; Protein Kinase Inhibitors; Pyrimidines; Real-Time Polymerase Chain Reaction; Selection, Genetic; Thiazoles; Trisomy | 2012 |
Blood consult: high Sokal risk chronic myeloid leukemia and suboptimal response.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Humans; Hydroxyurea; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Risk Factors; Thiazoles | 2011 |
Analysis of ABL kinase domain mutations conferring resistance to tyrosine kinase inhibitors in chronic myeloid leukemia cases from India.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Binding Sites; Blast Crisis; Catalytic Domain; Dasatinib; DNA, Neoplasm; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Gene Frequency; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Mutation, Missense; Piperazines; Point Mutation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Pyrimidines; Thiazoles | 2011 |
When evaluating parameter uncertainty is not enough: the case of dasatinib and nilotinib for imatinib-resistant chronic myeloid leukemia.
Topics: Benzamides; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Piperazines; Pyrimidines; Thiazoles | 2011 |
Cost-effectiveness of dasatinib and nilotinib for imatinib-resistant or -intolerant chronic phase chronic myeloid leukemia.
Topics: Antineoplastic Agents; Area Under Curve; Benzamides; Cost-Benefit Analysis; Dasatinib; Decision Support Techniques; Disease-Free Survival; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myeloid, Chronic-Phase; Models, Theoretical; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quality-Adjusted Life Years; Survival Analysis; Survival Rate; Thiazoles; Time Factors; United Kingdom | 2011 |
Responses to second-line tyrosine kinase inhibitors are durable: an intention-to-treat analysis in chronic myeloid leukemia patients.
Topics: Aniline Compounds; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Nitriles; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Survival Analysis; Thiazoles; Time Factors; Transcription, Genetic; Treatment Outcome | 2012 |
Rac2-MRC-cIII-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors.
Topics: Animals; Catalase; Disease Progression; DNA Damage; DNA, Neoplasm; Electron Transport; Electron Transport Complex III; Fusion Proteins, bcr-abl; Genomic Instability; Humans; Leukemia, Myeloid, Acute; Leukemia, Myeloid, Chronic-Phase; Membrane Potential, Mitochondrial; Methacrylates; Mice; Neoplasm Proteins; Neoplastic Stem Cells; Polycythemia Vera; rac GTP-Binding Proteins; RAC2 GTP-Binding Protein; Reactive Oxygen Species; Recombinant Fusion Proteins; Superoxide Dismutase; Thiazoles | 2012 |
EUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experience.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Clinical Trials, Phase II as Topic; Dasatinib; Europe; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Middle Aged; Piperazines; Predictive Value of Tests; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Research Design; Retrospective Studies; Survival Analysis; Thiazoles; Treatment Outcome; Validation Studies as Topic; Young Adult | 2012 |
CML treatment in Asia-Pacific region.
Topics: Adult; Antineoplastic Agents; Asia; Benzamides; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Middle Aged; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2012 |
Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia.
Topics: Aged; Antineoplastic Agents; Benzamides; Dasatinib; Disease-Free Survival; DNA Mutational Analysis; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Italy; Kaplan-Meier Estimate; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Mutation, Missense; Piperazines; Point Mutation; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Thiazoles | 2013 |
CML: the good, the better, and the difficult choices.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Female; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Male; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2012 |
BCR-ABL1 transcript at 3 months predicts long-term outcomes following second generation tyrosine kinase inhibitor therapy in the patients with chronic myeloid leukaemia in chronic phase who failed Imatinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Dasatinib; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Molecular Targeted Therapy; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Retrospective Studies; RNA, Messenger; RNA, Neoplasm; Thiazoles; Treatment Outcome | 2013 |
Panniculitis during dasatinib therapy for imatinib-resistant chronic myelogenous leukemia.
Topics: Aged; Antineoplastic Agents; Benzamides; Dasatinib; Female; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Middle Aged; Panniculitis; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2006 |
Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Dasatinib; Drug Approval; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Multicenter Studies as Topic; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; United States; United States Food and Drug Administration | 2008 |
Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.
Topics: Adult; Aged; Benzamides; Dasatinib; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Survival Rate; Thiazoles; Treatment Outcome | 2008 |
Isolated central nervous system lymphoid blast crisis in chronic myeloid leukaemia in major molecular remission.
Topics: Aged; Antineoplastic Agents; Benzamides; Blast Crisis; Central Nervous System; Dasatinib; Humans; Imatinib Mesylate; Immunophenotyping; Leukemia, Myeloid, Chronic-Phase; Male; Piperazines; Pyrimidines; Remission Induction; T-Lymphocytes; Thiazoles | 2008 |